```json
{
"content": [
{
"type": "paragraph",
"content": "The Rhinosinusitis Drug market is primarily divided by clinical application into acute rhinosinusitis (ARS), chronic rhinosinusitis (CRS), and postoperative rhinosinusitis (POS). ARS represents short‑term inflammation typically triggered by viral infection; its treatment window is limited to 4‑6 weeks, driving demand for rapid‑onset oral decongestants and short‑course antibiotics. CRS, defined by symptoms persisting beyond 12 weeks, accounts for the largest revenue share because of its high prevalence (≈10 % of the adult population) and the need for long‑term intranasal corticosteroids, biologics, and adjunctive antihistamines. POS emerges after sinus surgery, requiring targeted anti‑inflammatory regimens to prevent restenosis; although a niche segment, its higher per‑patient drug cost inflates its contribution to overall market value. According to 2025 estimates, ARS contributes roughly 30 % of total drug sales, CRS 55 % and POS 15 %. These proportions are reflected in the accompanying pie‑chart, illustrating the relative economic weight of each application within the Rhinosinusitis Drug segmentation."
},
{
"type": "paragraph",
"content": "The second tier of market taxonomy classifies Rhinosinusitis drugs by pharmacologic type, each reflecting distinct therapeutic pathways and cost structures. Intranasal corticosteroids remain the cornerstone for CRS management, generating the highest revenue due to chronic dosing and broad prescribing across primary care and otolaryngology. Oral antihistamines and leukotriene receptor antagonists serve as adjuncts in allergic‑triggered cases, contributing modest but steady sales volumes. Antibiotics—primarily amoxicillin‑clavulanate and doxycycline—are confined to ARS and
